Filing Analysis
Indaptus Therapeutics, Inc. entered into a Stock Purchase Agreement on June 17, 2026, to issue 20,000,000 shares of common stock at $0.60 per share to non-U.S. accredited investors. The private placement raised approximately $12,000,000 in gross proceeds.
🚩 Red Flags
- Significant dilution: Issuance of 20 million shares at a low price point ($0.60) suggests potential downward pressure on share price upon registration.
- Registration requirement: The company is obligated to file a registration statement within 90 days, which will likely lead to increased selling pressure in the public market.
📋 Key Facts
- Date of Agreement: June 17, 2026
- Total shares issued: 20,000,000 common stock
- Price per share: $0.60
- Aggregate gross proceeds: ~$12,000,000 (before expenses)
- The offering represents less than 20% of the Company's issued and outstanding Common Stock.
- Purchasers are non-U.S. accredited investors participating via Regulation S.
Indaptus Therapeutics announced a registered direct offering and private placement of 1,817,017 shares of common stock and an equal number of warrants. The deal includes significant dilution via warrant coverage and involves the company's CEO as a participant.
🚩 Red Flags
- Significant dilution: The issuance of warrants equal to the number of shares (1:1 warrant coverage) creates substantial potential dilution.
- Related-party transaction: The CEO is a purchaser in this offering.
- High cost of capital: 7.0% cash fee plus expenses and additional placement agent warrants increase the effective cost of the raise.
📋 Key Facts
- Total issuance: 1,817,017 shares of common stock and 1,817,017 warrants.
- Combined price for one share and one warrant: $1.175 per unit.
- Warrant exercise price: $1.05 per share.
- The CEO is participating in the offering, purchasing 42,553 shares and warrants.
- Paulson Investment Company, LLC acting as exclusive placement agent with a 7.0% cash fee plus $25,000 expenses.
- Placement Agent Warrants issued to Paulson for 124,212 shares at an exercise price of $1.3125.
Indaptus Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting date: November 12, 2024.
- Period covered: Quarter ended September 30, 2024.
Indaptus Therapeutics entered into a clinical supply agreement with BeiGene Switzerland GmbH to evaluate the combination of its product candidate, Decoy20, with BeiGene's anti-PD-1 antibody, tislelizumab. The study aims to treat patients with advanced solid tumors and is expected to begin in 2025 following FDA approval.
🚩 Red Flags
- Forward-looking statements explicitly mention 'conditions and events that raise substantial doubt regarding our ability to continue as going concern'.
- Explicitly mentions the need for additional capital due to lack of current cash flow.
- High research and development expenses noted in risk factors.
📋 Key Facts
- Agreement entered into on October 17, 2024, with BeiGene Switzerland GmbH.
- The partnership focuses on a Combination Study of Decoy20 and tislelizumab (BeiGene Product).
- Indaptus will pay all study costs except for the cost of the BeiGene Product.
- BeiGene will supply the anti-PD-1 antibody; Indaptus will supply Decoy20.
- The Combination Study is anticipated to begin in 2025, pending FDA approval.
Indaptus Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing serves to furnish the quarterly press release as Exhibit 99.1.
Indaptus Therapeutics, Inc. announced a registered direct offering and a private placement of common stock and warrants on August 7, 2024. The deal includes participation from the company's CEO and involves significant warrant issuance that will lead to future dilution.
🚩 Red Flags
- Significant potential dilution due to the issuance of warrants equal in number to the shares being offered.
- Related-party transaction: The CEO is a participant in the securities offering (Affiliate Securities).
- High placement agent fee of 9.0% plus expenses, which is substantial for a micro-cap company.
📋 Key Facts
- Registered direct offering of 1,643,837 shares of common stock.
- Private placement of warrants to purchase 1,643,837 shares of common stock.
- Combined price for one share and one warrant is $1.825 per unit.
- Warrant exercise price is set at $1.70 per share.
- The CEO participated in the offering, purchasing 84,932 shares and warrants.
- Paulson Investment Company, LLC acted as the exclusive placement agent with a 9.0% cash fee plus $50,000 in expenses.
- Warrants are immediately exercisable and expire in five years.
Indaptus Therapeutics, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 6, 2024. The meeting resulted in the election of three Class III directors and the approval of two key proposals regarding auditor ratification and a stock incentive plan.
📋 Key Facts
- Annual Meeting held on June 6, 2024, with approximately 50.09% of outstanding Common Stock represented (4,277,437 shares).
- Election of Roger J. Pomerantz, Michael J. Newman, and Jeffrey A. Meckler as Class III directors.
- Ratification of Haskell & White LLP as the independent registered public accounting firm for fiscal year 2024.
- Approval of the amendment and restatement of the 2021 Stock Incentive Plan, which includes increasing available shares and extending the evergreen provision.
Indaptus Therapeutics announced the successful advancement of its Phase I trial for Decoy20, specifically noting that the first patient has been dosed in the multi-dose portion following a Safety Review Committee evaluation. The company plans to present clinical data at the upcoming ASCO annual meeting.
🚩 Red Flags
- Forward-looking statements include explicit mention of 'conditions and events that raise substantial doubt regarding our ability to continue as going concern' and the need for additional capital due to lack of cash flow.
📋 Key Facts
- Successful advancement of Phase I trial investigating Decoy20.
- Safety Review Committee reviewed initial clinical data and approved progression.
- First patient has been dosed in the multi-dose portion of the study.
- The primary goal is to evaluate the safety of repeated administration of Decoy20.
- Company intends to move into combination studies with a checkpoint inhibitor.
Indaptus Therapeutics, Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Report date: May 8, 2024.
- Reporting period: Quarter ended March 31, 2024.
- The full press release is provided as Exhibit 99.1.
Indaptus Therapeutics announced that its Chief Scientific Officer will present new data regarding the research compound Decoy10 at the 2024 AACR Annual Meeting. The presentation focuses on confirming the mechanism of action for the company's proprietary platform technology.
🚩 Red Flags
- Forward-looking statements include a standard disclaimer regarding 'substantial doubt regarding our ability to continue as going concern' due to lack of cash flow (though this is boilerplate in the risk factors section).
📋 Key Facts
- Dr. Michael Newman (Founder and CSO) to present poster at 2024 AACR Annual Meeting in San Diego on April 10, 2024.
- Data concerns research compound Decoy10.
- The data aims to confirm the mechanism of action for the company's platform technology involving attenuated/killed non-pathogenic bacteria.
- Reported data suggests activation of multiple immune cell types including M1 macrophages, NK cells, dendritic cells, Th1 CD4, and CD8 T cells.
Indaptus Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 13, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- The information is furnished rather than filed under Section 18 of the Exchange Act.
Indaptus Therapeutics announced positive clinical results from the second cohort of its Phase 1 INDP-D101 trial for its lead compound, Decoy20. An independent Safety Review Committee recommended continuing the trial with multiple dosing schedules.
🚩 Red Flags
- Forward-looking statements include explicit mention of 'conditions and events that raise substantial doubt regarding our ability to continue as going concern' in the risk disclosures.
- Mention of the need for, and ability to raise, additional capital due to lack of current cash flow.
📋 Key Facts
- Positive results reported from the second cohort of Phase 1 INDP-D101 trial of lead compound Decoy20.
- Patients exhibited a broad immune response similar to the first cohort.
- Independent Safety Review Committee recommended continuing the trial and enrolling patients for multiple doses.
- The next stage aims to determine safety of multi-dosing and examine efficacy across multiple cancer types.
Indaptus Therapeutics, Inc. has amended and restated its bylaws to align with new SEC universal proxy rules and streamline stockholder nomination procedures.
📋 Key Facts
- The Board of Directors approved the Amended and Restated Bylaws on January 22, 2024.
- Amendments address compliance with SEC Rule 14a-19 (universal proxy rules).
- New bylaws require additional background information/disclosures for proposing stockholders and nominees.
- Prohibits submitting more director nominees than the number of directors up for election.
- Requires stockholders soliciting proxies to use a non-white proxy card color.
- Establishes federal district courts as the exclusive forum for certain Securities Act actions.